Johnson & Johnson is involved in the research and development, manufacture and sale of a range of products in the healthcare field. It is operating through three segments such as Consumer, Pharmaceutical and Medical Devices. It is the primary focussing products related to human health and well-being. The Consumer segment has some range of products that are used in baby care, oral care, skincare, over-the-counter pharmaceutical, women’s health, and wound care markets. These research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland, and the United Kingdom.
List of companies
COVID-19, which was first detected in December in Wuhan, China, has sickened more than 200,000 people worldwide and killed at least 8,500. There are no Food and Drug Administration-approved vaccines or therapies for the disease. There are some of the companies developing treatments or vaccines in the U.S. for COVID-19:
On March 17, NYSE JNJ or JNJ stock news at https://www.webull.com/quote/nyse-jnj is announced that it would help develop and distribute BioNTech SE’s COVID-19 vaccine candidate, though the deal excludes China. BioNTech plans to put the vaccine candidate into clinical trials in late April, in Germany and the U.S. It is testing the vaccine in collaboration with Shanghai Fosun Pharmaceutical Group Co. Ltd. in China. Pfizer and BioNTech for several years have said they would partner to develop mRNA-based influenza vaccines.
Gilead is a longtime drugmaker best known for developing the first major cure for hepatitis-C in Sovaldi, a therapy that changed the standard of care for that disease but also kicked off the national debate about drug pricing. Gilead is conducting a randomized, controlled clinical trial in Wuhan, testing redeliver as a treatment for mild to moderate forms of pneumonia in people with the virus.
GSK is another leading vaccine maker and it is having brought to market vaccines for human papillomavirus (HPV). On Feb. 3, it said the CEPI-funded University of Queensland will have access to the British drugmaker’s vaccine adjuvant platform technology, which is believed to both strengthen the response of a vaccine and limit the amount of vaccine needed per dose.
Vaxart was one of the first companies to announce plans to develop a vaccine when it did so Jan. 31. In March the clinical-stage company announced that Emergent BioSolutions will help develop and manufacture its oral vaccine candidate. For more stock news like Nasdaq cblk, you can check at https://www.webull.com/quote/nasdaq-cblk .